The board of directors at Vertex Pharmaceuticals, Cambridge, Mass., has named former Abbott Laboratories executive Dr. Jeffrey Leiden the company's president and CEO, effective in February. Until then, Matthew Emmens will remain the top executive, according to a Vertex news release.
Vertex names Leiden incoming CEO
Leiden, 56, has served as a board director at Vertex since 2009. According to the release, he began employment with Vertex this week in preparation for the succession early next year.
According to the succession plan, Leiden will become president and CEO on Feb. 1, when Emmens will step down as chairman, president and CEO and become executive chairman through May 2012. After May, Emmens plans to retire from full-time employment with Vertex but remain as a company director.
Leiden is currently a managing director at life-sciences venture-capital firm Clarus Ventures. Previously, he worked as president and COO at Abbott and as a practicing cardiologist and molecular biologist with the University of Chicago and Harvard Medical School, according to the release.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.